Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age

Clinical Pharmacology and Therapeutics

Volumn 90, Issue 5, 2011, Pages 693-700

  Desta, Z ^a   Kreutz, Y ^a   Nguyen, A T ^a   Li, L ^a   Skaar, T ^a   Kamdem, L K ^a   Henry, N L ^b   Hayes, D F ^b   Storniolo, A M ^a   Stearns, V ^c   Hoffmann, E ^d   Tyndale, R F ^d   Flockhart, D A ^a  

^a INDIANA UNIVERSITY   (United States)

^b UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2A6; CYTOCHROME P450 3A; EXEMESTANE; LETROZOLE;

AGE; ARTICLE; BODY MASS; BREAST CANCER; CONTROLLED STUDY; DNA DETERMINATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; FEMALE; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHARMACOGENOMICS; PHENOTYPE; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANDROSTADIENES; ANTINEOPLASTIC AGENTS; ARYL HYDROCARBON HYDROXYLASES; BODY MASS INDEX; BREAST NEOPLASMS; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; FEMALE; GENETIC VARIATION; GENOTYPE; HUMANS; MIDDLE AGED; NITRILES; PHARMACOGENETICS; POSTMENOPAUSE; PROSPECTIVE STUDIES; TRIAZOLES;

EID: 80055021257     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.174     Document Type: Article

References (27)

1. RYAN, K.J. Biological aromatization of steroids. J. Biol. Chem. 234, 268-272 (1959).
2. Bhatnagar, A.S., Häusler, A., Schieweck, K., Lang, M. & Bowman, R. Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new nonsteroidal aromatase inhibitor. J. Steroid Biochem. Mol. Biol. 37, 1021-1027 (1990).
3. Geisler, J., Haynes, B., Anker, G., Dowsett, M. & Lønning, P.E. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J. Clin. Oncol. 20, 751-757 (2002). (Pubitemid 34111382)
4. Geisler, J. et al. Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels. Clin. Cancer Res. 14, 6330-6335 (2008).
5. Thürlimann, B. et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med. 353, 2747-2757 (2005). (Pubitemid 43016814)
6. Coates, A.S. et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J. Clin. Oncol. 25, 486-492 (2007). (Pubitemid 350002953)
7. Henry, N.L. et al. A prospective study of aromatase inhibitor-associated musculoskeletal symptoms and abnormalities on serial high-resolution wrist ultrasonography. Cancer 116, 4360-4367 (2010).
8. Stearns, V. et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J. Natl. Cancer Inst. 95, 1758-1764 (2003). (Pubitemid 38008898)
9. Jin, Y. et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J. Natl. Cancer Inst. 97, 30-39 (2005).
10. Goetz, M.P. et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J. Clin. Oncol. 23, 9312-9318 (2005).
11. Femara* (letrozole) [prescribing information]. Quebec, Canada: Novartis Pharmaceutical Canada 〈http://www.novartis.ca/asknovartispharma/ download.htm?res=famvir-scrip-e.pdf&resTitleId=125〉 (2011).
12. Pfister, C.U. et al. Effect of age and single versus multiple dose pharmacokinetics of letrozole (Femara) in breast cancer patients. Biopharm. Drug Dispos. 22, 191-197 (2001). (Pubitemid 33133815)
13. Jeong, S., Woo, M.M., Flockhart, D.A. & Desta, Z. Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4′-methanol-bisbenzonitrile in vitro. Cancer Chemother. Pharmacol. 64, 867-875 (2009).
14. Murai, K., Yamazaki, H., Nakagawa, K., Kawai, R. & Kamataki, T. Deactivation of anti-cancer drug letrozole to a carbinol metabolite by polymorphic cytochrome P450 2A6 in human liver microsomes. Xenobiotica. 39, 795-802 (2009).
15. Mwenifumbo, J.C. et al. Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent. Hum. Mutat. 29, 679-688 (2008). (Pubitemid 351614592)
16. Al Koudsi, N., Ahluwalia, J.S., Lin, S.K., Sellers, E.M. & Tyndale, R.F. A novel CYP2A6 allele (CYP2A6*35) resulting in an amino-acid substitution (Asn438Tyr) is associated with lower CYP2A6 activity in vivo. Pharmacogenomics J. 9, 274-282 (2009).
17. Hukkanen, J., Jacob, P. 3rd & Benowitz, N.L. Metabolism and disposition kinetics of nicotine. Pharmacol. Rev. 57, 79-115 (2005). (Pubitemid 40283970)
18. Sinues, B. et al. CYP2A6 activity in a healthy Spanish population: effect of age, sex, smoking, and oral contraceptives. Hum. Exp. Toxicol. 27, 367-372 (2008).
19. Mwenifumbo, J.C., Zhou, Q., Benowitz, N.L., Sellers, E.M. & Tyndale, R.F. New CYP2A6 gene deletion and conversion variants in a population of Black African descent. Pharmacogenomics 11, 189-198 (2010).
20. Benowitz, N.L., Lessov-Schlaggar, C.N., Swan, G.E. & Jacob, P. 3rd. Female sex and oral contraceptive use accelerate nicotine metabolism. Clin. Pharmacol. Ther. 79, 480-488 (2006).
21. Ho, M.K. et al. Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers. Clin. Pharmacol. Ther. 85, 635-643 (2009).
22. Kamath, M.S., Aleyamma, T.K., Chandy, A. & George, K. Aromatase inhibitors in women with clomiphene citrate resistance: a randomized, double-blind, placebo-controlled trial. Fertil. Steril. 94, 2857-2859 (2010).
23. Ho, M.K., Mwenifumbo, J.C., Zhao, B., Gillam, E.M. & Tyndale, R.F. A novel CYP2A6 allele, CYP2A6*23, impairs enzyme function in vitro and in vivo and decreases smoking in a population of Black-African descent. Pharmacogenet. Genomics 18, 67-75 (2008). (Pubitemid 351161649)
24. Ogburn, E.T., Jones, D.R., Masters, A.R., Xu, C., Guo, Y. & Desta, Z. Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation. Drug Metab. Dispos. 38, 1218-1229 (2010).
25. Jeong, S., Nguyen, P.D. & Desta, Z. Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A. Antimicrob. Agents Chemother. 53, 541-551 (2009).
26. Henry, N.L. et al. Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res. Treat. 111, 365-372 (2008).
27. Mwenifumbo, J.C., Myers, M.G., Wall, T.L., Lin, S.K., Sellers, E.M. & Tyndale, R.F. Ethnic variation in CYP2A6*7, CYP2A6*8 and CYP2A6*10 as assessed with a novel haplotyping method. Pharmacogenet. Genomics 15, 189-192 (2005). (Pubitemid 40569906)